Global Mucolipidosis II (I Cell Disorder) Market Is Anticipated to Surge Approximately $15.8 Billion By 2030

The global mucolipidosis II (I cell disorder) market size was nearly $12.8 Billion in 2022 and is anticipated to surge to approximately $15.8 Billion by 2030 along with recording the highest growth rate of nearly 8.8% from 2023 to 2030.

Mucolipidosis II (I cell disorder) is termed as I-cell disease and is a lysosomal storage disorder occurring as a result of enzyme N-acetylglucosamine-1-phosphotransferase activity resulting in the inability of internalizing enzymes into lysosomes. Apart from this, the ailment is a rare as well as inherited one. Furthermore, it is also named as sialidosis and the condition is classified as lysosomal storage disorder (LSD). In this disorder, genetic irregularities hinder the normal activity of lysosomes in human tissues.

Rise in incidences of mucolipidosis II (I cell disorder) among the global population will multiply the growth of the global mucolipidosis II (I cell disorder) market. The burgeoning need for a large number of medicines for treating mucolipidosis II (I cell disorder) symptoms such as delays in the growth of gross and fine motor skills coupled with financial support from public & private organizations for inventing new modes of treatment will augment the global market growth. In addition to this, the rise in the demand for novel healthcare treatments for metabolic disorders will provide impetus to the global market in the coming decade.

Nevertheless, high treatment costs are anticipated to put brakes on the expansion of the mucolipidosis II (I cell disorder) industry in the years to come. However, approval of new drugs by regulatory bodies along with highlighting as well as funding of research & development projects for finding a cure for mucolipidosis II (I cell disorder) will help the industry explore new horizons of growth in the near future.

 The global mucolipidosis II (I cell disorder) market is sectored into symptoms, treatment, end-user, and region.                        

The symptoms segment of the mucolipidosis II (I cell disorder) market is sub-segmented into deafness, lack of muscle tone (hypotonia), abnormal spine curvature, changing proportion of mental retardation, low growth of gross & fine motor skills, and others segments. Furthermore, the low growth of gross & fine motor skills segment, which contributed for over 25% of the global market share in 2022, is anticipated to retain its leading position even in the foreseeable future. The segmental growth in the next eight years can be credited to the lack of growth of gross & fine motor skills seen in the children post-birth as they suffered from mucolipidosis II (I cell disorder) after birth.

On the basis of route of administration, the mucolipidosis II (I cell disorder) industry across the globe is divided into antibiotics, hip replacement, experimental therapies, physical therapy, and others segments. The antibiotics segment, which led the treatment segment in 2022, is projected to contribute the largest share of the global market in the forecasting timeline. The growth of the segment in the coming years can be due to large-scale prescriptions of antibiotics by physicians for treating mucolipidosis II (I cell disorder).

Based on end-user, the global mucolipidosis II (I cell disorder) market is sectored into specialty clinics, homecare, hospitals, and others segments.  

Furthermore, North America, which dominated the revenue share of the global mucolipidosis II (I cell disorder) market in 2022, is prognosed to continue its numero uno position in the regional market during the next eight years. The regional market surge over 2023-2030 can be subject to the easy availability of robust healthcare infrastructure facilities in the region. Apparently, a prominent rise in healthcare spending by governments of the countries such as the U.S. and Canada will account lucratively towards the market elevation in  North America.

On the other hand, the mucolipidosis II (I cell disorder) industry in the Asia-Pacific region is slated to record the highest CAGR of 7.5% in the forecasting years. The regional market expansion in the coming years can be owing to an increase in the number of patients in countries such as India, China, Indonesia, and Thailand. Moreover, unmet medical needs in these countries will uplift the expansion of the industry in the Asia-Pacific zone.

Browse the full “Mucolipidosis II (I Cell Disorder) Market By Symptoms (Deafness, Lack of Muscle Tone (Hypotonia), Abnormal Spine Curvature, Changing Proportion of Mental Retardation, Low Growth of Gross & Fine Motor Skills, and Others), By Treatment (Antibiotics, Physical Therapy, Hip Replacement, Experimental Therapies, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030.” Report at https://www.zionmarketresearch.com/report/mucolipidosis-ii-i-cell-disorder-market

Recent Developments:

• In the first quarter of 2021, the U.S. FDA provided orphan drug distribution status to two gene therapies referred to as M6P Gene Therapy for Gaucher disorder with an objective of treating inherited metabolic disorder mucolipidosis. The initiative is likely to expand the scope of the mucolipidosis II (I cell disorder) industry across the globe.
• In the second half of 2022, researchers at University of Michigan in the U.S. found a new gene TMEM251 in a rare disorder referred to as mucolipidosis type II, a lysosomal storage disorder, which causes swelling in the heart & abdomens as well as malformation in the bones. Moreover, the ailment also causes internal organ edema as well as skeletal dysplasia.

Key players in the global mucolipidosis II (I cell disorder) market include:

• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Amgen Inc
• Mylan N.V.
• Sanifit
• Teva Pharmaceutical Industries Ltd
• Alkem Labs
• Cipla Inc.
• Hope Pharmaceuticals
• BSN medical
• Zydus Cadila.

The global mucolipidosis II (I cell disorder) market is segmented as follows:

By Symptoms

• Deafness
• Lack of Muscle Tone (Hypotonia)
• Abnormal Spine Curvature
• Changing Proportion of Mental Retardation
• Low Growth of Gross & Fine Motor Skills
• Others

By Treatment

• Antibiotics
• Physical Therapy
•  Hip Replacement
•  Experimental Therapies
•  Others

By End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com